Immunovant, Inc.
IMVTDrugs in Pipeline
6
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Aug 6, 2026
TomorrowMarket Overview
Stock performance and key metrics
2 upcoming, 0 past
IMVT Earnings Report
EPS Est: $-0.66 | FQ end 2026-06 | Call: 2026-08-06 15:00:00
Batoclimab Phase 3 Results Expected
Primary completion for Batoclimab trial (NCT05517447) in Thyroid Eye Disease
Sobi's gout drug passes Phase 3 test
SourceHow IMVT's past catalysts played out
IMVT-1402
Chronic Inflammatory Demyelinating Polyneuropathy
Batoclimab
Thyroid Eye Disease
Batoclimab 680 mg SC weekly
Generalized Myasthenia Gravis
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly
Chronic Inflammatory Demyelinating Polyneuropathy
RVT-1401
Myasthenia Gravis
IMVT-1401 (batoclimab)
Graves Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
IMVT-1402 | Phase 3 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
Batoclimab | Phase 3 | Thyroid Eye Disease | - | - |
Batoclimab 680 mg SC weekly | Phase 3 | Generalized Myasthenia Gravis | - | - |
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly | Phase 2 | Chronic Inflammatory Demyelinating Polyneuropathy | - | - |
RVT-1401 | Phase 2 | Myasthenia Gravis | - | - |
IMVT-1401 (batoclimab) | Phase 2 | Graves Disease | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Immunovant, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Immunovant, Inc.'s (IMVT) pipeline across Phase 3, Phase 2. Its lead program is IMVT-1402 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Immunovant, Inc.'s next FDA catalyst?→
Immunovant, Inc.'s (IMVT) next tracked catalyst is a Earnings expected August 6, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track IMVT biotech catalysts?→
Add IMVT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Immunovant, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.